Here the authors develop ucenprubart (LY3454738) for treating AD and find, in a randomized, multiple arms, multicenter, placebo controlled, and dose-escalating phase 1 trial (NCT03750643 ...

Total hip BMD increases were associated with reduced risk for vertebral and all clinical fractures across active control or sequential therapy trials.